Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionJennison Associates Llc
Latest Disclosed Ownership6,705,746 shares
Ownership 2.80%
Jennison Associates Llc ownership in VRTX / Vertex Pharmaceuticals Incorporated

2015-02-10 - Jennison Associates Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,705,746 shares of Vertex Pharmaceuticals Incorporated (US:VRTX). This represents 2.8 percent ownership of the company.

Jennison Associates Llc has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2015-02-10 2015-02-10 13G/A 6,705,746 2.80
2014-02-10 2014-02-10 13G/A 13,474,878 5.80
2013-02-13 2013-02-13 13G/A 17,766,754 8.20
2012-02-14 2012-02-14 13G 10,479,739 5.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,740,059 -509,482 -15.68 1,223,546 -16.95 0.8414
2026-01-30 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,249,541 -205,406 -5.95 1,473,212 8.88 0.8845
2025-10-30 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,454,947 -2,696,558 -43.84 1,353,095 -50.59 0.7877
2025-08-01 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,151,505 1,089,063 21.51 2,738,650 11.58 1.6242
2025-05-05 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,062,442 744,680 17.25 2,454,373 41.16 1.7214
2025-01-24 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,317,762 -1,232,624 -22.21 1,738,763 -32.64 1.0559
2024-11-08 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,550,386 851,054 18.11 2,581,373 17.19 1.6025
2024-08-05 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,699,332 -83,042 -1.74 2,202,671 10.18 1.4118
2024-05-02 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,782,374 837,461 21.23 1,999,080 24.54 1.3366
2024-02-01 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,944,913 147,248 3.88 1,605,146 21.55 1.1962
2023-10-31 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,797,665 -7,976 -0.21 1,320,600 -1.39 1.1212
2023-08-03 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,805,641 -774,160 -16.90 1,339,243 -7.19 1.0985
2023-04-26 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,579,801 -535,739 -10.47 1,442,958 -2.32 1.3235
2023-02-09 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,115,540 359,719 7.56 1,477,266 7.28 1.4971
2022-11-01 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,755,821 2,983,253 168.30 1,377,000 175.68 1.3693
2022-08-02 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,772,568 1,422,478 406.32 499,492 446.71 0.4985
2022-05-11 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 350,090 -433,299 -55.31 91,363 -46.89 0.0673
2022-02-08 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 783,389 -45,970 -5.54 172,032 14.35 0.1091
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 829,359 37,531 4.74 150,437 -5.77 0.0973
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 791,828 76,039 10.62 159,656 3.80 0.1058
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 715,789 -3,033,565 -80.91 153,816 -82.64 0.1126
2021-02-05 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,749,354 140,270 3.89 886,122 -9.77 0.6317
2020-11-04 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,609,084 -809,397 -18.32 982,104 -23.44 0.7896
2020-08-06 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,418,481 56,726 1.30 1,282,729 23.59 1.1594
2020-05-06 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,361,755 790,506 22.14 1,037,880 32.73 1.2608
2020-02-07 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,571,249 -2,406,492 -40.26 781,925 -22.79 0.7888
2019-11-08 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,977,741 -366,718 -5.78 1,012,749 -12.95 1.0698
2019-08-06 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,344,459 -455,977 -6.71 1,163,447 -6.99 1.1634
2019-05-10 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,800,436 -141,185 -2.03 1,250,940 8.75 1.2431
2019-02-06 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,941,621 739,128 11.92 1,150,296 -3.78 1.2869
2018-11-08 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,202,493 1,139,486 22.51 1,195,468 38.93 1.1008
2018-08-02 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,063,007 -1,712,321 -25.27 860,509 -22.07 0.8390
2018-04-20 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,775,328 1,237,421 22.34 1,104,243 33.06 1.0979
2018-01-25 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,537,907 -479,859 -7.97 829,911 -9.29 0.8196
2017-11-03 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,017,766 962,644 19.04 914,941 40.45 0.9371
2017-08-04 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,055,122 3,626,368 253.81 651,454 316.97 0.6910
2017-08-02 2017-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,428,754 125,744 9.65 156,234 62.76 0.1676
2017-04-28 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,427,529 156,100
2017-08-02 2016-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,303,010 -3,877,751 -74.85 95,993 -78.75 0.1072
2017-02-06 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,301,776 95,902
2016-11-01 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,180,761 2,205,961 74.15 451,814 76.56 0.4870
2016-08-03 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,974,800 1,920,658 182.20 255,892 205.38 0.2808
2016-05-03 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,054,142 -1,029,650 -49.41 83,794 -68.04 0.0879
2016-02-10 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,083,792 -250,915 -10.75 262,204 7.84 0.2574
2015-11-06 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,334,707 -2,770,547 -54.27 243,136 -61.43 0.2587
2015-08-03 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,105,254 -1,443,237 -22.04 630,397 -18.40 0.5779
2015-06-25 2015-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,548,491 -157,255 -2.35 772,525 -3.03 0.7078
2015-05-04 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,548,491 772,525
2015-06-25 2014-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 6,705,746 -3,743,006 -35.82 796,643 -32.11 0.7449
2015-02-06 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,705,746 -3,743,006 796,643 0.7450
2014-11-12 2014-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 10,448,752 -1,416,257 -11.94 1,173,499 4.46 1.0885
2014-11-05 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,448,752 -1,416,257 1,173,499 1.1180
2014-08-08 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,865,009 -739,038 -5.86 1,123,379 26.03 1.0321
2014-05-07 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,604,047 -870,831 -6.46 891,358 -10.97 0.8523
2014-02-10 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,474,878 -469,415 -3.37 1,001,183 -5.30 0.9821
2013-11-13 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 13,944,293 -3,254,728 -18.92 1,057,256 -23.04 1.1083
2013-08-05 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,199,021 17,199,021 1,373,686 1.5453
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2021-08-12 2021-06-30 13F VERTEX PHARMACEUTICALS CALL OPTIONS Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS CALL OPTIONS Call 30,000 6,447 n/a n/a n/a
2014-11-05 2014-09-30 13F VERTEX PHARMACEUTICALS CALL OPTIONS Call 0 -100.00 0 -100.00 n/a n/a n/a
2014-08-08 2014-06-30 13F VERTEX PHARMACEUTICALS CALL OPTIONS Call 450,000 42,606 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2017-08-02 2017-03-31 13F/A VERTEX PHARMACEUTICALS PUT OPTIONS Put 0 -100.00 0 -100.00 n/a n/a n/a
2017-08-02 2016-12-31 13F/A VERTEX PHARMACEUTICALS PUT OPTIONS Put 29,700 -88.12 2,188 -87.62 n/a n/a n/a
2017-02-06 2016-12-31 13F VERTEX PHARMACEUTICALS PUT OPTIONS Put 29,700 2,188 n/a n/a n/a
2014-05-07 2014-03-31 13F VERTEX PHARMACEUTICALS PUT OPTIONS Put 250,000 17,680 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.